Optimal Use of Fluoroquinolones in the Intensive Care Unit Setting

被引:12
作者
Rotschafer, John C. [1 ]
Ullman, Mary A. [2 ]
Sullivan, Christopher J. [3 ]
机构
[1] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
[2] Reg Hosp, Dept Clin Pharm, St Paul, MN USA
[3] Fairview Hosp Syst, Minneapolis, MN USA
关键词
Fluoroquinolone antibiotics; Intensive care unit; Pharmacodynamics; PSEUDOMONAS-AERUGINOSA; QUINOLONE RESISTANCE; DNA TOPOISOMERASES; RISK-FACTOR; PHARMACODYNAMICS; CIPROFLOXACIN; LEVOFLOXACIN; SPARFLOXACIN; PNEUMONIA; SELECTION;
D O I
10.1016/j.ccc.2010.11.005
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Fluoroquinolones have become a staple antimicrobial in a variety of settings for a wide spectrum of infectious diseases. Although fluoroquinolones have been associated with a broad spectrum of adverse events, the side effect profile is generally acceptable. Their use in the intensive care unit as empiric therapy is becoming compromised due to the development of multiple drug resistant gram negative pathogens and collateral damage with C difficile & MRSA. Fluoroquinolones should be used along with another antibiotic of different chemical structure, mechanism of action, and pharmacodynamic profile to ensure adequate initial antimicrobial coverage and maximize the likelihood of a favorable clinical and microbiologic response.
引用
收藏
页码:95 / +
页数:13
相关论文
共 37 条
  • [31] Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus
    Schmitz, FJ
    Hofmann, B
    Hansen, B
    Scheuring, S
    Lückefahr, M
    Klootwijk, M
    Verhoef, J
    Fluit, A
    Heinz, HP
    Köhrer, K
    Jones, ME
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (04) : 481 - 484
  • [32] Sicor-Pharmaceuticals, 2006, CIPR MED INF
  • [33] Cellular roles of DNA topoisomerases: A molecular perspective
    Wang, JC
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (06) : 430 - 440
  • [34] Treatment with Fluoroquinolones or with β-Lactam-β-Lactamase Inhibitor Combinations Is a Risk Factor for Isolation of Extended-Spectrum-β-Lactamase-Producing Klebsiella Species in Hospitalized Patients
    Wener, Kenneth M.
    Schechner, Vered
    Gold, Howard S.
    Wright, Sharon B.
    Carmeli, Yehuda
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) : 2010 - 2016
  • [35] Application of fluoroquinolone pharmacodynamics
    Wright, DH
    Brown, GH
    Peterson, ML
    Rotschafer, JC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (05) : 669 - 683
  • [36] Optimizing use of quinolones in the critically ill
    Yang, Jenny C.
    Tsuji, Brian T.
    Forrest, Alan
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 28 (06) : 586 - 595
  • [37] In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM
    Ziha-Zarifi, I
    Llanes, C
    Köhler, T
    Pechere, JC
    Plesiat, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) : 287 - 291